Author name: John Policano

Ten years ago, a little girl was in the battle of her life against a foe she couldn’t possibly comprehend. Two years previously, she was diagnosed with acute lymphoblastic leukemia at the age of 5. No parent wants to receive the news that their child has a potentially lethal disease, but for the majority of […]

A Brief History of the CAR T Cell Field While chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of blood-forming tissue cancers (i.e., hematologic malignancies), major limitations hinder their widespread application. Decades of CAR T cell therapy efforts, starting with “first generation” CAR T cell therapies in the 1990s and leading to

At Umoja, we know that a cancer immunotherapy is only as good as the patients it reaches. We can do the best, most innovative, most exciting science at the bench, but if the manufacturing process is not scalable, the effort will be too large to ultimately meet the needs of all patients who might benefit.

Looking back over the past year, it is gratifying as CEO to reflect on the extraordinary progress we’ve made at Umoja Biopharma.   This year has had no shortage of major accomplishments for the company. Topping the list is our recent closing of an oversubscribed $210 million Series B funding round. We view our success